Abstract:Objectives: As a part of NHS' Innovation and Technology Payment programme (ITP), pregnant women were offered Placental Growth Factor (PLGF)-based testing to help rule out pre-eclampsia (PET) - a serious condition that affects approximately 2.3% of the female population. The study was aimed to evaluate the implementation of PLGF-based testing at United Lincolnshire Trust Hospitals (ULHT). Study design: The soluble FMS like Tyrosine kinase 1/placental growth factor (sFlt-1/PLGF) ratio test was launched at ULHT on 8th October 2020. The project involved a review of an electronic maternity database (MEDWAY) for all women who had sFLT-1/PLGF ratio test performed at ULHT over a 5-month period (October 2020-February 2021). The sFlt-1/PLGF ratio was recorded alongside clinical outcome. Women were classified as low, moderate, and high risk for development of PET if the sFlt-1/PLGF ratio was ≤ 38, 39-84 and ≥ 85 respectively. Reasons for admission were further investigated and adherence to the sFLT-1/PLGF protocol was monitored to evaluate staff performance. Data was then statistically analysed with χ2 and T-test for categorical and continuous variables respectively. Finally, sensitivity and specificity of the sFLT-1/PLGF was assessed with an ROC curve. Results: A total of 236 women had sFlt-1/PLGF ratio test performed in a five-month period. A two-time point analysis (a "during implementation" and "post implementation phase") showed a significant decrease in the admission rates in the post-implementation phase in low-risk group (28.5% during implementation vs 11.3% post-implementation, P < 0.05). Further analysis showed greater staff adherence to the sFLT-1/PLGF protocol in the post-implementation period. The high-risk group demonstrated shorter time from test to delivery, earlier gestational age at delivery and lower birth weight (P < 0.05). Conclusions: The study outcomes resulted in a successful submission of a business case. Successful triage of low-risk women at the point where historically admissions were considered reduced clinical workload and enabled better utilisation of resources by allowing focussed care on high-risk women for an optimal maternal and perinatal outcome.

Polymeric optical fiber biosensor with PAMAM dendrimer-based surface modification and PlGF detection for pre-eclampsia diagnosis

Enhancing Pregnancy Care: Harnessing Label‐Free Immunosensors for Pre‐Eclampsia Detection Using PdNPs/Poly(3,5‐Diaminobenzoic Acid) Modified Glassy Carbon Electrodes

Systematic design and evaluation of aptamers for VEGF and PlGF biomarkers of Preeclampsia

Bowtie Nanoantenna LSPR Biosensor for Early Prediction of Preeclampsia

Lateral Flow Assay for Preeclampsia Screening Using DNA Hairpins and Surface-Enhanced Raman-Active Nanoprobes Targeting hsa-miR-17-5p

Plasmonic pregnancy detector: enhancing sensitivity with SPR sensor

Nanochannel-driven rapid capture of sub-nanogram level biomarkers for painless preeclampsia diagnosis

Automated electrochemiluminescence immunoassay for serum PlGF levels in women with singleton pregnancy at 9-13 weeks of gestation predicts preterm preeclampsia: a retrospective cohort study

Sensitive Fluorescence Analysis of Pregnancy Plasma Associated Protein A in Amniotic Fluid Based on the Plasma Superstructure Enhanced Carbon Polymer Dots

Fluorescence lifetime imaging microscopy for early diagnosis and severity prediction of preeclampsia with Nile Blue probe

Implementing placental-growth-factor (PLGF) measurements in suspected pre-eclampsia----Challenges in clinical practice

Molecularly Imprinted Plasmonic Substrates for Specific and Ultrasensitive Immunoassay of Trace Glycoproteins in Biological Samples.

Predicting the onset of preeclampsia by longitudinal monitoring of metabolic changes throughout pregnancy with Raman spectroscopy

Long-term monitoring of blood biomarkers related to intrauterine growth restriction using AgNPs SERS tags-based lateral flow assay

Electro-responsive Molecularly Imprinted Polymers (E-MIPs) for Rapid Detection of Progesterone in Human Serum Samples

Highly porous poly(l-lactic) acid nanofibers as a dual-signal paper-based bioassay platform for in vitro diagnostics

Disposable and cost-effective label-free electrochemical immunosensor for prolactin based on bismuth sulfide nanorods with polypyrrole

Sandpaper-templated Stretchable Immunosensing Electrodes for Sub-picomolar Progesterone Detection

Validation of a New Kit for Preeclampsia Screening: A Comprehensive Analysis

Poly(3-Hexylthiophene) Based Bioelectronic Interface Using Conducting Nanofibers (CNFs) for the Sensitive Determination of Folate Receptor Cancer Biomarkers in Human Plasma

Routine ante-natal screening using maternal risk factors and biomarkers for preeclampsia in 11-13+6 weeks of gestation